Julie McArthur
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 382 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $23.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Merck$940
- Abbott$671
- Novartis$647
- E.r. Squibb & Sons, L.L.C.$591
- Amgen$451
- plus $4K from 24 others
What the payments were for
- Travel & lodging$5376%
- Food & beverage$8,24992%
- Education$1331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 38 | $2,067 |
| Merck | 54 | $940 |
| Abbott | 16 | $671 |
| Novartis | 47 | $647 |
| E.r. Squibb & Sons, L.L.C. | 32 | $591 |
| Amgen | 26 | $451 |
| Actelion Pharmaceuticals US, Inc. | 8 | $425 |
| Johnson & Johnson | 23 | $414 |
| Esperion Therapeutics, Inc. | 18 | $336 |
| Bayer | 12 | $319 |
| Pfizer | 16 | $293 |
| Boehringer Ingelheim | 17 | $292 |
| AstraZeneca | 16 | $277 |
| Sanofi-aventis U.S. LLC | 9 | $167 |
| Heartflow, Inc. | 1 | $132 |
| Amarin Pharma, Inc. | 7 | $116 |
| Novo Nordisk | 5 | $105 |
| Philips North America LLC | 5 | $100 |
| Alnylam Pharmaceuticals Inc. | 4 | $90 |
| Azurity Pharmaceuticals, Inc. | 4 | $78 |
| Kowa Pharmaceuticals America, Inc. | 4 | $66 |
| Kestra Medical Technology Services, Inc. | 3 | $58 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $45 |
| Impulse Dynamics (USA) Inc. | 3 | $44 |
| Cvrx, Inc. | 2 | $37 |
| Lexicon Pharmaceuticals, Inc. | 2 | $31 |
| Atricure, Inc. | 1 | $30 |
| Scpharmaceuticals Inc. | 2 | $29 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$845
- CARDIOMEMS$377
- FFRct$132
- Kerendia$124
- UPTRAVI$122
- OPSUMIT$122
- CAMZYOS$122
- Watchman$118
- CardioMEMS HF System$105
- WATCHMAN Access System$100
How this compares
$8,918 in reported general payments places this provider in the 90th percentile of 370 medical providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 555 | $489,482 |
| XareltoRivaroxaban | 129 | $106,677 |
| CamzyosMavacamten | 12 | $106,168 |
| EntrestoSacubitril/Valsartan | 76 | $77,269 |
| JardianceEmpagliflozin | 29 | $25,914 |
| Repatha SureclickEvolocumab | 39 | $24,456 |
| FarxigaDapagliflozin Propanediol | 26 | $18,079 |
| BrilintaTicagrelor | 21 | $17,148 |
| VascepaIcosapent Ethyl | 16 | $16,673 |
| Atorvastatin Calcium | 494 | $9,036 |
| Metoprolol Succinate | 407 | $7,012 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 36 | $5,316 |
| Amiodarone Hcl | 206 | $4,784 |
| Losartan Potassium | 219 | $3,510 |
| Nebivolol Hcl | 27 | $3,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $293 | $489,482555 claims |
| Johnson & JohnsonXarelto | $414 | $106,677129 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $591 | $106,16812 claims |
| NovartisEntresto | $647 | $77,26976 claims |
| AstraZenecaFarxiga, Brilinta | $277 | $35,22747 claims |
| Boehringer IngelheimJardiance | $292 | $25,91429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 medical providers in Oklahoma.
Other medical in Tulsa
- Matthew DohlmanTulsa$39K
- Tara LinvilleTulsa$19K
- Debra OdomTulsa$17K
- Kristen HaunTulsa$15K
- Monica AbbottTulsa$11K
- Ryan ChoplinTulsa$10K
- Ashley BiggsTulsa$8K
- Erin JonesTulsa$6K
- Caroline ParkerTulsa$6K
- J ThomasTulsa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.